Pulsenmore Ltd. (PLSM) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Pulsenmore Ltd. stock $3.02, price $1.51, upside +100.0%, quality 59 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
11‑month range $1.51 – $2,151 · fair‑value band $1.99 – $3.78 · the $1.51 price screens below the $3.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Pulsenmore Ltd. Ordinary Shares in your weekly email
Every Wednesday you see whether Pulsenmore Ltd. Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products. The company was incorporated in 2014 and is based in Omer, Israel.
Stock analysis
Pulsenmore Ltd. (PLSM) currently trades at $1.51, while our model-based Fair Value estimate is $3.02, implying the stock looks roughly 50% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.99 (bear) to $3.78 (bull), the price of $1.51 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Pulsenmore Ltd. Ordinary Shares reported revenue of 40.0M ILS in FY2025 versus 1.6M ILS in FY2021, a compound +124.5%/yr. Reported net income was −15.9M ILS in FY2025.
Key figures
Market cap $9.6M Micro · EPS (TTM) $−1.30 · Net margin −66.0% · Return on equity −45.2% · Return on assets (EBIT) −21.1% (5-year average) · Revenue growth (YoY) +52.0% · Free cash flow −33.0M ILS · Net cash 20.0M ILS.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 100%, PLSM screens cheaper than that median.
Fair Value models
Bear$1.99Fair Value $3.02Bull$3.78
Price $1.51 · Upside +100.0%
Capped: our models arrive at a very high value here. We deliberately show a more cautious Fair Value.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $15,740, on Nov 4, 2026.
BuyElazar SonnenscheinChief Executive Officer, Director9,259 shares at $1.70$15,740Nov 4, 2026
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+315.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+55.8%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,390.2% (2021) → −30.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Pulsenmore Ltd. Ordinary Shares with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside+100.0% · Top 25%
Profitability
Return on assets−15.6% · Bottom 25%
Net margin (12 months)−66.0% · Bottom 25%
Operating margin (12 months)0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)52.0% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Pulsenmore Ltd. (PLSM) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $3.02 versus a price of $1.51, about +100% upside (undervalued).
What is the fair value of PLSM?
Our model-based fair value for Pulsenmore Ltd. is $3.02 (as of Nov 8, 2026), built from audited fundamentals. The current price: $1.51.
What is the quality score of PLSM?
Pulsenmore Ltd. has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pulsenmore Ltd. (PLSM)?
Our model-based price target is the fair value of $3.02 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $1.99, optimistic scenario $3.78. It is a calculation from audited fundamentals, not an analyst target.
What is the Pulsenmore Ltd. Ordinary Shares stock forecast for 2026?
Our models put fair value at $3.02, about +100% upside versus a price of $1.51 (undervalued). Cautious scenario $1.99, optimistic scenario $3.78. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Pulsenmore Ltd. (PLSM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pulsenmore Ltd. it is $3.02 per share (as of Nov 8, 2026), against a price of $1.51. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Pulsenmore Ltd. Ordinary Shares stock overvalued or undervalued in 2026?
As of Nov 8, 2026, PLSM trades below its calculated fair value: price $1.51, fair value $3.02, a gap of about +100% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PLSM?
No. The price is what the market pays today ($1.51); the fair value is what the company's own numbers justify ($3.02). For Pulsenmore Ltd. the two are $1.51 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pulsenmore Ltd. Ordinary Shares worth?
The market values Pulsenmore Ltd. at about $9.6M (market capitalisation, as of Nov 8, 2026). Per share that is $1.51; our models calculate a fair value of $3.02 per share.
What do the bullish and bearish scenarios say about PLSM?
Our models span a range for Pulsenmore Ltd.: cautious scenario $1.99, base $3.02, optimistic $3.78 per share (as of Nov 8, 2026, price $1.51). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pulsenmore Ltd. (PLSM)?
Balance-sheet figures for Pulsenmore Ltd. (as of Nov 8, 2026): return on equity −45.2%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
Which stocks are comparable to Pulsenmore Ltd. Ordinary Shares?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pulsenmore Ltd. Ordinary Shares stock attractive at the current price?
The data as of Nov 8, 2026: price $1.51, calculated fair value $3.02 (+100%), Quality Score 59/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PLSM calculated?
We run Pulsenmore Ltd. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $3.02 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pulsenmore Ltd. currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pulsenmore Ltd. (PLSM)?
The closing price on Nov 6, 2026 was $1.51. Our model-based fair value is $3.02, about +100% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pulsenmore Ltd. Ordinary Shares right now?
The price is below even our cautious bear case ($1.99). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (59/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($1.99 to $3.78) leaves room in how you read the outcome.
Key figures of Pulsenmore Ltd.
How large is the market capitalisation of Pulsenmore Ltd. (PLSM)?
The market capitalisation of Pulsenmore Ltd. is $9.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Pulsenmore Ltd. (PLSM)?
Earnings per share at Pulsenmore Ltd. are $−1.30. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pulsenmore Ltd. (PLSM)?
The net margin of Pulsenmore Ltd. is −66.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pulsenmore Ltd. (PLSM)?
The return on equity (ROE) of Pulsenmore Ltd. is −45.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pulsenmore Ltd. (PLSM)?
On an EBIT basis the return on assets of Pulsenmore Ltd. is −21.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Pulsenmore Ltd. (PLSM)?
Revenue at Pulsenmore Ltd. is growing +52.0% versus a year earlier (3y avg +55.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pulsenmore Ltd. (PLSM) generate?
The free cash flow of Pulsenmore Ltd. is −33.0M ILS (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Pulsenmore Ltd. (PLSM) hold?
Pulsenmore Ltd. holds more cash than debt, 20.0M ILS net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Pulsenmore Ltd. Ordinary Shares in the live analysis
One click puts Pulsenmore Ltd. Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
